<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6768452</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0218226</article-id><article-id pub-id-type="publisher-id">PONE-D-19-14579</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Europe</subject><subj-group><subject>European Union</subject><subj-group><subject>Portugal</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Europe</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Multivariate Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Multivariate Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Bioinformatics</subject><subj-group><subject>Sequence Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Ethnicities</subject><subj-group><subject>European People</subject><subj-group><subject>Portuguese People</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Evolutionary Biology</subject><subj-group><subject>Evolutionary Systematics</subject><subj-group><subject>Phylogenetics</subject><subj-group><subject>Phylogenetic Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Taxonomy</subject><subj-group><subject>Evolutionary Systematics</subject><subj-group><subject>Phylogenetics</subject><subj-group><subject>Phylogenetic Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Computer and Information Sciences</subject><subj-group><subject>Data Management</subject><subj-group><subject>Taxonomy</subject><subj-group><subject>Evolutionary Systematics</subject><subj-group><subject>Phylogenetics</subject><subj-group><subject>Phylogenetic Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Drivers of HIV-1 transmission: The Portuguese case</article-title><alt-title alt-title-type="running-head">Drivers of HIV-1 transmission in Portugal</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Pineda-Pe&#x000f1;a</surname><given-names>Andrea-Clemencia</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7928-3087</contrib-id><name><surname>Pingarilho</surname><given-names>Marta</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Guangdi</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vrancken</surname><given-names>Bram</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Libin</surname><given-names>Pieter</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gomes</surname><given-names>Perp&#x000e9;tua</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Camacho</surname><given-names>Ricardo Jorge</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Theys</surname><given-names>Kristof</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barroso Abecasis</surname><given-names>Ana</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><collab>on behalf of the Portuguese HIV-1 Resistance Study Group</collab><xref ref-type="author-notes" rid="fn001"><sup>&#x000b6;</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Molecular Biology and Immunology Department, Fundaci&#x000f3;n Instituto de Inmunolog&#x000ed;a de Colombia (FIDIC) and Basic Sciences Department, Universidad del Rosario, Bogot&#x000e1;, Colombia</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Metabolism and Endocrinology, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Artificial Intelligence Lab, Department of Computer Science, Vrije Universiteit Brussel, Brussels, Belgium</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Laborat&#x000f3;rio de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Centro de Investiga&#x000e7;&#x000e3;o Interdisciplinar Egas Moniz (CiiEM), Instituto Universit&#x000e1;rio Egas Moniz, Caparica, Portugal</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Blackard</surname><given-names>Jason</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Cincinnati College of Medicine, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>ABA received funding from two commercial sources: L&#x000d3;real Portugal, through the research award L'Or&#x000e9;al Portugal Medals of Honor for Women in Science (2012) and Gilead G&#x000e9;nese HIVLatePresenters. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="other" id="fn001"><p>&#x000b6; Membership of the Portuguese HIV-1 Resistance Study Group is provided in the Acknowledgments.</p></fn><corresp id="cor001">* E-mail: <email>ana.abecasis@ihmt.unl.pt</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>9</issue><elocation-id>e0218226</elocation-id><history><date date-type="received"><day>24</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Pineda-Pe&#x000f1;a et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Pineda-Pe&#x000f1;a et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0218226.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Portugal has one of the most severe HIV-1 epidemics in Western Europe. Two subtypes circulate in parallel since the beginning of the epidemic. Comparing their transmission patterns and its association with transmitted drug resistance (TDR) is important to pinpoint transmission hotspots and to develop evidence-based treatment guidelines.</p></sec><sec id="sec002"><title>Methods</title><p>Demographic, clinical and genomic data were collected from 3599 HIV-1 naive patients between 2001 and 2014. Sequences obtained from drug resistance testing were used for subtyping, TDR determination and transmission clusters (TC) analyses.</p></sec><sec id="sec003"><title>Results</title><p>In Portugal, transmission of subtype B was significantly associated with young males, while transmission of subtype G was associated with older heterosexuals. In Portuguese originated people, there was a decreasing trend both for prevalence of subtype G and for number of TCs in this subtype. The active TCs that were identified (i.e. clusters originated after 2008) were associated with subtype B-infected males residing in Lisbon. TDR was significantly different when comparing subtypes B (10.8% [9.5&#x02013;12.2]) and G (7.6% [6.4&#x02013;9.0]) (p = 0.001).</p></sec><sec id="sec004"><title>Discussion</title><p>TC analyses shows that, in Portugal, the subtype B epidemic is active and fueled by young male patients residing in Lisbon, while transmission of subtype G is decreasing. Despite similar treatment rates for both subtypes in Portugal, TDR is significantly different between subtypes.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>HIVERA: Harmonizing Integrating Vitalizing European Research on HIV/Aids</institution></funding-source><award-id>249697</award-id><principal-award-recipient><name><surname>Abecasis</surname><given-names>Ana</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>L&#x02019;Or&#x000e9;al Portugal, Comiss&#x000e3;o Nacional da Unesco</institution></funding-source><principal-award-recipient><name><surname>Abecasis</surname><given-names>Ana</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>FCT for funds to GHTM</institution></funding-source><award-id>UID/Multi/04413/2013</award-id></award-group><award-group id="award004"><funding-source><institution>Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia</institution></funding-source><award-id>PTDC/DTP-EPI/7066/2014</award-id><principal-award-recipient><name><surname>Abecasis</surname><given-names>Ana</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution>Gilead G&#x000e9;nese HIVLatePresenters</institution></funding-source><award-id>HIVLatePresenters</award-id><principal-award-recipient><name><surname>Abecasis</surname><given-names>Ana</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution>National Nature Science Foundation of China</institution></funding-source><award-id>31571368</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Guangdi</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution>Innovation-driven Project of Central South University</institution></funding-source><award-id>2016CX031</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Guangdi</given-names></name></principal-award-recipient></award-group><award-group id="award008"><funding-source><institution>Fonds voor Wetenschappelijk Onderzoek &#x02013; Flanders (FWO)</institution></funding-source><award-id>G.0692.14</award-id><principal-award-recipient><name><surname>Theys</surname><given-names>Kristof</given-names></name></principal-award-recipient></award-group><award-group id="award009"><funding-source><institution>Fonds voor Wetenschappelijk Onderzoek &#x02013; Flanders (FWO)</institution></funding-source><award-id>G.0611.09N</award-id><principal-award-recipient><name><surname>Theys</surname><given-names>Kristof</given-names></name></principal-award-recipient></award-group><award-group id="award010"><funding-source><institution>European Union&#x02019;s Horizon 2020 research and innovation programme</institution></funding-source><award-id>634650</award-id><principal-award-recipient><name><surname>Theys</surname><given-names>Kristof</given-names></name></principal-award-recipient></award-group><award-group id="award011"><funding-source><institution>Hercules Foundation and the Flemish Government</institution></funding-source><award-id>KAN2012 1.5.249.12</award-id><principal-award-recipient><name><surname>Theys</surname><given-names>Kristof</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by European Funds through grant &#x02018;Bio-Molecular and Epidemiological Surveillance of HIV Transmitted Drug Resistance, Hepatitis Co-Infections and Ongoing Transmission Patterns in Europe - BEST HOPE - (project funded through HIVERA: Harmonizing Integrating Vitalizing European Research on HIV/Aids, grant 249697)&#x02019; to ABA; by L&#x02019;'Or&#x000e9;al Portugal Medals of Honor for Women in Science 2012 (financed through L&#x02019;'Or&#x000e9;al Portugal, Comiss&#x000e3;o Nacional da Unesco and Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e Tecnologia (FCT - <ext-link ext-link-type="uri" xlink:href="http://www.fct.pt">http://www.fct.pt</ext-link>)) to ABA; by FCT for funds to GHTM-UID/Multi/04413/2013; by the MigrantHIV project (financed by FCT: PTDC/DTP-EPI/7066/2014 to ABA; by Gilead G&#x000e9;nese HIVLatePresenters to ABA; by the National Nature Science Foundation of China (31571368) to GL; by the Innovation-driven Project of Central South University (2016CX031) to GL; by the Fonds voor Wetenschappelijk Onderzoek &#x02013; Flanders (FWO) grant G.0692.14, and G.0611.09N to KT; by the VIROGENESIS project that receives funding from the European Union&#x02019;s Horizon 2020 research and innovation programme under grant agreement No 634650 to KT. The computational resources and services used in this work were provided by the Hercules Foundation and the Flemish Government &#x02013; department EWI-FWO Krediet aan Navorsers (Theys, KAN2012 1.5.249.12.) to KT. KT is supported by a postdoctoral grant from FWO. BV is supported by a postdoctoral grant of the FWO (Fonds Wetenschappelijk Onderzoek &#x02013; Vlaanderen). L&#x02019;'Or&#x000e9;al Portugal, Comiss&#x000e3;o Nacional da Unesco and Gilead G&#x000e9;nese HIVLatePresenters had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Portugal had one of the highest rates of HIV diagnoses in Europe in 2016, with 10.0 diagnoses per 100,000 population [<xref rid="pone.0218226.ref001" ref-type="bibr">1</xref>]. Despite the fact that new diagnoses have decreased within the country in the last years [<xref rid="pone.0218226.ref002" ref-type="bibr">2</xref>], the patterns of HIV-1 transmission remain uncertain. Phylogenetic analyses are powerful tools to understand the dynamics of viral transmission [<xref rid="pone.0218226.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0218226.ref007" ref-type="bibr">7</xref>] and to provide insights for designing prevention policies.</p><p>According to the European and Portuguese guidelines for antiretroviral treatment [<xref rid="pone.0218226.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0218226.ref009" ref-type="bibr">9</xref>], a baseline resistance test should be performed to determine transmitted drug resistance (TDR), which can impact the first-line antiretroviral response [<xref rid="pone.0218226.ref010" ref-type="bibr">10</xref>]. The last nationwide survey was carried out in 2003 and showed 7.8% of TDR [<xref rid="pone.0218226.ref011" ref-type="bibr">11</xref>]. Surveillance of TDR is important for the development of treatment guidelines, especially in Portugal where considerable migration from Portuguese speaking countries occurs, including some African countries where the levels of TDR are increasing along with the recent scaling-up of NRTI and NNRTI based treatments [<xref rid="pone.0218226.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0218226.ref013" ref-type="bibr">13</xref>].</p><p>The epidemiology of HIV-1 in Portugal is unique in comparison to other European countries. Most of the epidemic is caused by parallel sub-epidemics of subtype B and subtype G [<xref rid="pone.0218226.ref014" ref-type="bibr">14</xref>]. Until 2005, subtype B accounted for approximately 40% of infections and subtype G accounted for 30% [<xref rid="pone.0218226.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0218226.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0218226.ref015" ref-type="bibr">15</xref>]. The present large-scale cohort provides the unique opportunity to compare the temporal evolution of the parallel epidemics of these subtypes in the same country. Herein, we use transmission cluster reconstruction to understand the drivers of HIV-1 transmission in Portugal and its correlation with primary drug resistance: prevalence of TDR and factors associated with the spread of TDR. The characterization of HIV-1 transmission in the Portuguese epidemic can help to design targeted prevention strategies.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Patients and methods</title><sec id="sec007"><title>Study population</title><p>The protocol was in accordance with the Declaration of Helsinki and approved by the Ethical Committee of Centro Hospitalar de Lisboa Ocidental (108/CES-2014). The Portuguese HIV-1 drug resistance database contains retrospective anonymized patients&#x02019; information, including demographic, clinical and genotype resistance testing data from patients followed up in 22 hospitals located around the country. All patients&#x02019; data collected from the RegaDB database was generated during routine clinical care [<xref rid="pone.0218226.ref016" ref-type="bibr">16</xref>]. The inclusion criteria for the analysis of TDR was age older than 18 years and no history of antiretroviral treatment between January 2001 and December 2014. This cohort is named PT-naive, hereafter. The genomic data included the protease and the reverse transcriptase (HXB2: 2253&#x02013;3554) obtained through population sequencing using the ViroSeq assay.</p></sec><sec id="sec008"><title>Drug resistance assessment</title><p>Surveillance drug resistance mutations (SDRM) were defined according to the WHO list [<xref rid="pone.0218226.ref017" ref-type="bibr">17</xref>]. The impact of TDR was evaluated with the HIVdb v.7.0 and Rega v.9.1.0 (<ext-link ext-link-type="uri" xlink:href="http://sierra2.stanford.edu/sierra/servlet/JSierra?action=algSequenceInput">http://sierra2.stanford.edu/sierra/servlet/JSierra?action=algSequenceInput</ext-link>).</p></sec><sec id="sec009"><title>Subtyping and transmission cluster analyses</title><p>HIV-1 subtypes were determined with Rega v3 and COMET v.1.0 [<xref rid="pone.0218226.ref018" ref-type="bibr">18</xref>][<xref rid="pone.0218226.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0218226.ref020" ref-type="bibr">20</xref>]. Subtype G and CRF14_BG were merged in a single group (named hereafter G dataset), given that: i) this genomic region has the same evolutionary origin for G and CRF14_BG strains; ii) the origin of the CRF14_BG strains occurred in the Iberian Peninsula [<xref rid="pone.0218226.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0218226.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0218226.ref021" ref-type="bibr">21</xref>]; iii) previously, we reported that the two tools and the manual phylogenetic analyses were not conclusive whether the sequences were G or CRF14_BG in the present cohort [<xref rid="pone.0218226.ref017" ref-type="bibr">17</xref>]; iv) there was no recombination breakpoint in the genomic regions of protease and reverse transcriptase in these sequences. A statistical sub-analysis was performed considering only &#x0201c;pure" subtype G strains (excluding CRF14_BG), defined by the concordant assignment of the two subtyping tools [<xref rid="pone.0218226.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0218226.ref020" ref-type="bibr">20</xref>], to evaluate how this affected our findings (Tables C and D in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>).</p><p>For the TCs analysis, the dataset was complemented with controls retrieved from: (i) the treated population of the Portuguese cohort between 2001 and 2014, (ii) the 50 best-matched sequences to each sequence of the total cohort of subtype B and G, as retrieved by BLAST (<ext-link ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov/Blast.cgi">http://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>), (iii) all HIV-1 <italic>pol</italic> subtype B and G sequences available from Portugal in the Los Alamos database (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/">http://www.hiv.lanl.gov</ext-link>) [<xref rid="pone.0218226.ref022" ref-type="bibr">22</xref>]. Three subtype D or B reference sequences were used as the outgroup. Sequences with low quality, duplicates and clones were deleted. The resulting dataset was aligned with Muscle [<xref rid="pone.0218226.ref023" ref-type="bibr">23</xref>] and verified for codon-correctness using VIRULIGN [<xref rid="pone.0218226.ref024" ref-type="bibr">24</xref>]. To avoid convergent evolution, SDRMs were removed [<xref rid="pone.0218226.ref017" ref-type="bibr">17</xref>]. The final subtype B and G datasets consisted of 7497 and 4372 sequences, both with a length of 1173 nucleotides (IQR:1173&#x02013;1173).</p><p>A Maximum likelihood tree was constructed with the GTR+ 4&#x00393; nucleotide substitution model and 1000 bootstraps, as implemented in RAxML version 7.5.5. The transmission clusters (TC) were identified with Cluster Picker using a threshold that included a genetic distance of 0.045 and &#x02265; 80% bootstrap replicates [<xref rid="pone.0218226.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0218226.ref025" ref-type="bibr">25</xref>]. To evaluate the effect of the definition of TCs in the results, sensitivity analyses were performed with varying genetic distances (0.015, 0.030, 0.045, 0.060) and bootstrap supports (70, 90, 95, 98).</p><p>TCs identified were confirmed with Bayesian Markov Chain Monte Carlo (MCMC) inference, as implemented in BEAST v1.8.2 [<xref rid="pone.0218226.ref026" ref-type="bibr">26</xref>]. The temporal signal of the TCs datasets was evaluated with TempEst [<xref rid="pone.0218226.ref027" ref-type="bibr">27</xref>]. The uncorrelated log-normal relaxed molecular clock with a discretized GTR substitution model and the Bayesian Skygrid coalescent model were used [<xref rid="pone.0218226.ref028" ref-type="bibr">28</xref>]. Three separate MCMC chains were run for at least 100 million generations. Convergence was determined with Tracer using a burn-in of 10% (<ext-link ext-link-type="uri" xlink:href="http://beast.bio.ed.ac.uk/Tracer">http://beast.bio.ed.ac.uk/Tracer</ext-link>). The maximum clade credibility (MCC) tree was constructed with TreeAnnotator after discarding the burn-in, and visualized with FigTree v1.4.2 (<ext-link ext-link-type="uri" xlink:href="http://tree.bio.ed.ac.uk/">http://tree.bio.ed.ac.uk</ext-link>).</p><p>The TCs analyses included the following definitions: (i) A pair was defined as exactly two patients included in a TC, one of them from the PT-naive cohort; (ii) a cluster &#x02265;3 included three or more patients, with at least one from the PT-naive cohort (iii) a TDR-cluster-&#x02265;3 or TDR-pair contain at least one PT-naive patient with a sequence harboring a SDRM; (iv) an onward-TDR-cluster had &#x02265;3 patients with the same SDRM in the majority of the patients and at least one from the PT-naive cohort with TDR, which suggest onward transmission of TDR; and (v) active-TCs included transmission of HIV-1 or/and TDR that involves at least one PT-naive patient within a time frame of &#x02264;5 years. The time frame was calculated as the maximum length of time between the ancestral node and the most recent tip (year 2014) of the MCC trees [<xref rid="pone.0218226.ref029" ref-type="bibr">29</xref>]. As such, a TC could be separated in two or more active sub-clusters, since such sub-clusters may indicate the population which actively transmitted HIV-1 or TDR in the last years.</p></sec><sec id="sec010"><title>Statistical analyses</title><p>Statistical analyses were performed to understand and compare the dynamics of the subtype B and G sub-epidemics in the PT-naive cohort, specifically the factors associated with transmission of HIV-1B and HIV-1G, independently of TDR; and the factors associated with transmission of TDR. All these analyses were performed within and compared between subtypes. Sensitivity analyses (<xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>) were performed and, if a result was discordant in the sensitivity analysis, the difference is clearly stated throughout the manuscript.</p><p>The Fisher's exact test or regression techniques were conducted to compare between proportions, while the Mann Whitney U test or the t-test were used to compare between median or mean values for continuous variables, as appropriate. Binomial logistic regression was used to determine the factors associated with each epidemic, TDR, and clustering. The Bonferroni method was used for multiple testing adjustments. The level of statistical significance was set at 5%. The analyses were performed with the statistical R software v.3.2.1.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Study population</title><p>The PT-naive cohort included a total of 3599 patients, 2042 with subtype B (56.7%) and 1557 (43.3%) with G. The socio-demographic factors are shown in Tables A and B in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>.</p></sec><sec id="sec013"><title>Subtype B sub-epidemic is associated with young males living in Lisbon</title><p>Regarding the socio-demographic factors associated with the transmission of the sub-epidemic B versus G in the PT-naive cohort, there were significant differences between the two sub-epidemics for age, gender, risk of transmission, residence in Lisbon, and CD4 count in the univariate analyses, while in the multivariate analyses younger age (Odds Ratio (OR): 0.83 for every increase of 10 years (<sup>10-years</sup>), 95% Confidence interval: 0.79&#x02013;0.89, p&#x0003c;0.0001), male (OR: 2.66, 2.28&#x02013;3.09, p&#x0003c;0.0001) and living in Lisbon (OR: 1.44, 1.25&#x02013;1.66, p&#x0003c;0.0001) were significantly associated with subtype B infections.</p></sec><sec id="sec014"><title>Transmission of subtype B is driven by young males</title><p>There were 497 TCs that included 61.2% of the subtype B PT-naive cohort (<xref rid="pone.0218226.t001" ref-type="table">Table 1</xref>) When comparing the cohort outside versus inside TCs of subtype B in the multivariate analysis, individuals inside subtype B TCs were younger (OR<sup>10-years</sup>: 0.83, 0.76&#x02013;0.90, p&#x0003c;0.0001) and more frequently male (OR 1.42, 1.14&#x02013;1.78, p = 0.001) than individuals outside the TCs, indicating that young males are driving this sub-epidemic in Portugal as we have identified in other European cohorts [<xref rid="pone.0218226.ref005" ref-type="bibr">5</xref>].</p><table-wrap id="pone.0218226.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0218226.t001</object-id><label>Table 1</label><caption><title>Characteristics of the transmission clusters (TCs) in the general cohort and in the cohort with TDR.</title></caption><alternatives><graphic id="pone.0218226.t001g" xlink:href="pone.0218226.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="3" colspan="1">Characteristic</th><th align="center" colspan="5" rowspan="1">General population</th><th align="center" colspan="5" rowspan="1">TDR population in TCs</th></tr><tr><th align="center" colspan="2" rowspan="1">B</th><th align="center" colspan="2" rowspan="1">G</th><th align="center" rowspan="2" colspan="1">p-value</th><th align="center" colspan="2" rowspan="1">B</th><th align="center" colspan="2" rowspan="1">G</th><th align="center" rowspan="2" colspan="1">p-value</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Clusters</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<bold>Number of cohort clusters</bold></td><td align="center" rowspan="1" colspan="1">497</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">333</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Median size (IRQ)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;3)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;3)</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(2&#x02013;4)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;4)</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Number of Cluster &#x02265;3</underline></td><td align="center" rowspan="1" colspan="1">221</td><td align="center" rowspan="1" colspan="1">44.5</td><td align="center" rowspan="1" colspan="1">132</td><td align="center" rowspan="1" colspan="1">39.6</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">51.2</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">48.4</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median size (IRQ)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;5)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;5)</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;6)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;6)</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<bold>Number of active clusters</bold></td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">24.1</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">14.1</td><td align="center" rowspan="1" colspan="1">0.0003</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">31.7</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Median size (IRQ)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;3)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;2)</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;3)</td><td align="center" rowspan="1" colspan="1">2,5</td><td align="center" rowspan="1" colspan="1">(2&#x02013;3)</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Number of Cluster &#x02265;3</underline></td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">7.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">13.4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median size (IRQ)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(3&#x02013;4)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(3&#x02013;3.25)</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(3&#x02013;4)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(-)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<bold>Number of clusters that suggests onward TDR</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Number of Cluster</underline></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">29.3</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">22.6</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median size (IRQ)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(3&#x02013;4)</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;5)</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Still active</underline></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median size (IRQ)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(2&#x02013;2.5)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(-)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Patients</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<bold>Number in cohort clusters</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Number of cohort and controls</td><td align="center" rowspan="1" colspan="1">1636</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">972</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">343</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Number of cohort patients</td><td align="center" rowspan="1" colspan="1">1250</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">726</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">146</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Cluster &#x02265;3</underline></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort and controls</td><td align="center" rowspan="1" colspan="1">1084</td><td align="center" rowspan="1" colspan="1">66.3</td><td align="center" rowspan="1" colspan="1">570</td><td align="center" rowspan="1" colspan="1">58.6</td><td align="center" rowspan="1" colspan="1">0.0001</td><td align="center" rowspan="1" colspan="1">263</td><td align="center" rowspan="1" colspan="1">76.7</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort patients</td><td align="center" rowspan="1" colspan="1">828</td><td align="center" rowspan="1" colspan="1">66.2</td><td align="center" rowspan="1" colspan="1">411</td><td align="center" rowspan="1" colspan="1">56.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">67.8</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">58.8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<bold>Number in active clusters</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Number of cohort and controls</td><td align="center" rowspan="1" colspan="1">302</td><td align="center" rowspan="1" colspan="1">18.5</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">10.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">21.9</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">0.0089</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Number of cohort patients</td><td align="center" rowspan="1" colspan="1">286</td><td align="center" rowspan="1" colspan="1">22.9</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">12.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">27.4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">7.8</td><td align="center" rowspan="1" colspan="1">0.0225</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Cluster &#x02265;3</underline></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort and controls</td><td align="center" rowspan="1" colspan="1">134</td><td align="center" rowspan="1" colspan="1">8.2</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">12.5</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6.0</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort patients</td><td align="center" rowspan="1" colspan="1">128</td><td align="center" rowspan="1" colspan="1">10.2</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">13.0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2.0</td><td align="center" rowspan="1" colspan="1">N</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;<bold>Number in clusters that suggests onward TDR</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Cluster &#x02265;3</underline></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort and controls</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">27.7</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">32.0</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort patients</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">49.3</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">41.2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;<underline>Still active</underline></td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number or cohort and controls</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6.0</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Number of cohort patients</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">17.8</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: IQR: interquartile range, n: sample, NS: No significant, TCs: Transmission clusters TDR: transmitted drug resistance, % percentage.</p></fn></table-wrap-foot></table-wrap><p>The number of PT-naive patients included in TCs had a peak in 1999 for clusters &#x02265;3 followed by a steady decrease, while the peak in the number of patients in pairs occurred in 2002 followed by an up and down curve (<xref ref-type="fig" rid="pone.0218226.g001">Fig 1A</xref>). This peak in 1999 includes 38% of the PT-naive cohort, which suggests transmission of HIV was still ongoing for subtype B despite the introduction of HAART.</p><fig id="pone.0218226.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0218226.g001</object-id><label>Fig 1</label><caption><title>Number of na&#x000ef;ve patients in transmission clusters of the PT-na&#x000ef;ve cohort vs time of origin (i.e. most recent common ancestor- MRCA) of those TCs.</title><p>The number of naive patients included in the TCs is represented in the y-axis while the year of origin is in the x-axis. The type of clusters is presented as pairs (dashed line) and clusters &#x02265;3 (solid line) for B (dark red) and G-like (blue). (<bold>A</bold>) Time of origin (MRCA) of non-drug resistant TCs in the PT-na&#x000ef;ve cohort (<bold>B</bold>) Time of origin (MRCA) of all TDR TCs in the PT-na&#x000ef;ve cohort. Time of introduction of Highly Effective Antiretroviral Therapy (HAART) (1996), time of start of needle and syringe program (NSP) in Portugal (1993), time of increasing number of regimen options (2001) and time of introduction of potent drugs (2007) are marked as grey dotted lines in the x-axis.</p></caption><graphic xlink:href="pone.0218226.g001"/></fig></sec><sec id="sec015"><title>Transmission of subtype G is decreasing in native Portuguese people</title><p>There were 333 TCs that contained 46.6% of the G PT-naive cohort (<xref rid="pone.0218226.t001" ref-type="table">Table 1</xref> and Tables A and B in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>). None of the socio-demographic or clinical factors were significantly associated with transmission of subtype G. Interestingly, a decreasing trend in the percentage of native Portuguese people included in TCs was observed since 2005 (p = 0.006, <xref ref-type="fig" rid="pone.0218226.g002">Fig 2A</xref>).</p><fig id="pone.0218226.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0218226.g002</object-id><label>Fig 2</label><caption><p>Prevalence of subtype G in Portuguese originated people during the period of the study (years in the y-axis) when considering the ones who were in transmission clusters (<bold>A</bold>). The light blue shades are the confidence intervals of the proportion of patients for a period of two years (dark blue line). The first period was excluded given the few numbers of patients but significance did not change. (<bold>B</bold>) Prevalence (dot) and 95% confidence intervals of the Transmitted drug resistance for subtypes B (red) and G (dark blue) for the PT-naive cohort and for each drug group. Geographical differences were observed for TDR when Lisbon was compared with other regions. Significant differences are shown with an asterisk. Abbreviations: NRTI: Nucleoside reverse transcriptase inhibitors, NNRTI: non-NRTI, PI: Protease inhibitors; TCs: Transmission clusters, vs: versus, %: percentage.</p></caption><graphic xlink:href="pone.0218226.g002"/></fig><p>The numbers of PT-naive patients included in TCs had an up and down curve, as clusters &#x02265; 3 originated more frequently in 2001 followed by a steady decrease, while this peak occurred in 2005 for pairs (<xref ref-type="fig" rid="pone.0218226.g001">Fig 1A</xref>). In contrast with subtype B, most PT-naive patients were involved in TCs originated before the introduction of HAART; i.e. G: 45 TCs included 266 patients (17.1%) vs B: 63 TCs with 114 patients (9%); (p&#x0003c;0.0001).</p></sec><sec id="sec016"><title>In the last years, subtype B transmission was predominant and occurred between patients sampled in Portugal</title><p>In a sub-analysis considering only TCs originating in the last five years of the cohort (active-TCs), 24.1% (120/497) and 14.1% (47/333) TCs were subdivided in smaller active-TCs for subtype B and G, respectively (<xref rid="pone.0218226.t001" ref-type="table">Table 1</xref>). These active-TCs included mainly subtype B patients (75.5%, 286/379 compared to 23.9% (93/379) for subtype G (p&#x0003c;0.0001)). Socio-demographic characteristics of the patients in active-TCs and the total cohort were similar (Tables A and B in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>). Males (OR: 6.56, 3.63&#x02013;11.85, p&#x0003c;0.0001) and patients living in Lisbon (OR: 2.03, 1.12&#x02013;3.69, p&#x0003c;0.05) were associated with the active transmission of subtype B when compared with G. Since we completed our cohort with controls retrieved from other databases, it is important to note the active-TCs included mainly controls sampled in Portugal for both subtypes, indicating transmission of HIV-1 predominantly occurs between patients in Portugal.</p></sec><sec id="sec017"><title>TDR in subtype G occurs more frequently in patients followed-up in hospitals outside the Lisbon area</title><p>In the subtype B PT-naive cohort, the prevalence of TDR was 10.8% [221/2042; 9.5&#x02013;12.2%], 4.9% [102/2042; 4.1&#x02013;6.0] for nucleoside reverse transcriptase inhibitors (NRTIs), 4.7% [96/2042; 3.8&#x02013;5.7%] for Non-NRTIs (NNRTIs) and 3.9% [80/2042; 3.1&#x02013;4.8] for protease inhibitors (PIs) (<xref ref-type="fig" rid="pone.0218226.g002">Fig 2B</xref>). Dual class resistance was found in 19.5% and triple class was found in 3.2% of subtype B patients. Regarding the socio-economical and clinical factors, none of the factors were associated with TDR in the multivariate analysis for this subtype.</p><p>For subtype G, the TDR prevalence in the PT-naive cohort was 7.6% [118/1557, 6.4&#x02013;9.0], 1.7% [27/1557; 1.2&#x02013;2.5] for NRTIs, 4.9% [76/1557; 3.9&#x02013;6.0] for NNRTIs and 2.2% [34/1557; 1.6&#x02013;3.0] for PIs. Dual and triple class resistance were found, respectively, in 12.7% and 1.7% of subtypes G patients. Older age, heterosexual transmission and living outside of <italic>Lisboa</italic> and <italic>Vale do Tejo</italic> regions were significantly associated with TDR in subtype G (<xref ref-type="fig" rid="pone.0218226.g002">Fig 2B</xref>). The multivariate analysis showed people living outside of the <italic>Lisboa</italic> and <italic>Vale do Tejo</italic> regions associated with TDR in subtype G (OR: 1.87, 1.22&#x02013;2.88).</p><p>When subtype B and G were compared, there were higher prevalence of TDR (OR: 1.47, 1.17&#x02013;1.89, p = 0.001), NRTIs TDR (OR: 2.98, 1.92&#x02013;4.76, p &#x0003c;0.0001) and PIs TDR (OR: 1.83, 1.20&#x02013;3.83, p = 0.003) for subtype B. Subtype B patients with TDR were also older (OR<sup>10-years</sup>: 0.68, 0.55&#x02013;0.82, p = 0.001) and more frequently male (OR: 3.10, 1.83&#x02013;5.24, p&#x0003c;0.0001).</p></sec><sec id="sec018"><title>Active and onward transmission of TDR for subtype B is driven by males living in Lisbon</title><p>Eighty-two subtype B TCs had at least one patient from the PT-naive cohort harboring viruses with SDRMs (TDR-TCs, <xref rid="pone.0218226.t001" ref-type="table">Table 1</xref>). The TDR-TCs included 66.1% (n = 146/221) of the total number of patients with TDR compared to 43.2% for G (n = 51/118; p&#x0003c;0.0001; Table A in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>), indicating more active transmission of TDR in subtype B. When the Portuguese treated population was included as complementary database for the TCs analyses, it was observed that nearly half (n = 39/82) of the TDR-TCs for subtype B included at least one treated patient. However, the number of treated patients in subtype B TDR-TCs decreased over time since 2006 (p&#x0003c;0.0001).</p><p>The origin of subtype B TDR-TCs was mainly between 1999 and 2005: 23 pairs and 26 clusters &#x02265;3 represented 60% (n = 88/146) of the PT-naive cohort in clusters harbouring viruses with SDRMs (<xref ref-type="fig" rid="pone.0218226.g001">Fig 1B</xref>). There were no socio-demographic factors associated with the transmission of SDRMs for subtype B.</p><p>Twenty-six TDR-TCs originated in the last five years for subtype B (active clusters; <xref rid="pone.0218226.t001" ref-type="table">Table 1</xref> and Table A in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>). This population was similar to the population involved in subtype B active clusters: male (85%, 64/75), living in <italic>Lisboa</italic> and <italic>Vale do Tejo</italic> region and &#x0003c;35 years old (both 65.3%). Twenty-four TDR-TCs had evidence of onward transmission of SDRMs, those were mainly thymidine analog mutations (TAMs) and/or NNRTIs SDRMs. Seven out of those 24 TDR-TCs with evidence of onward transmission were still active in the last five years. The characteristics of the population reflected that male (77%, 20/26) and living <italic>Lisboa</italic> and <italic>Vale do Tejo</italic> region (69.2%) still drive the transmission of TDR.</p><p>As expected, when transmission of TDR was compared in the subtype B and G sub-epidemics, subtype B was significantly associated with transmission of TDR (OR: 1.75, 1.24&#x02013;2.49, p = 0.0007). In this subtype, younger age (OR<sup>10-years</sup>: 0.53, 0.39&#x02013;0.73, p&#x0003c;0.0001) and males (OR: 4.53, 1.92&#x02013;10.66 p = 0.0005) were consistently associated with transmission of TDR.</p></sec><sec id="sec019"><title>The onward and active transmission of TDR for subtype G is limited</title><p>Thirty-one subtype G TDR-TCs included 43.2% (51/118) patients from the PT-naive cohort harbouring viruses with SDRMs (<xref rid="pone.0218226.t001" ref-type="table">Table 1</xref> and Table B in <xref ref-type="supplementary-material" rid="pone.0218226.s001">S1 File</xref>). Nearly half (n = 15/31) of the TDR-TCs for subtype G included at least one treated patient.</p><p>When considering the time origin of TDR-TCs, 35.3% patients of the PT-naive cohort were involved in TDR-TCs originated between 1996 and 1999, followed by 27.5% between 2000&#x02013;2003 (<xref ref-type="fig" rid="pone.0218226.g001">Fig 1B</xref>). Then, mainly pairs including 27.5% and 25.5% of the TDR-patients were originated in 2000&#x02013;2003 and 2004&#x02013;2008, respectively. There were no socio-demographic factors or time trends associated with transmission of TDR. When including controls and comparing people transmitting TDR versus without TDR in TCs of subtype G, age (median: 44, IQR: 34&#x02013;54 versus 37, 31&#x02013;46, p = 0.002), and viral load were significant in the univariate analysis (median: 4.9 Log-copies/mm<sup>3</sup>, IQR: 4.4&#x02013;5.7 versus 4.6, 3.9&#x02013;5.2, p = 0.03). However, those were no longer significant in the multivariate analyses. When TDR-TCs &#x02265;3 were analysed including controls, residence outside of the <italic>Lisboa</italic> and <italic>Vale do Tejo</italic> region was significantly associated with TDR within subtype G in the multivariate analysis (OR: 2.96, 1.29&#x02013;6.79, p = 0.01). Interestingly, this geographical pattern was no longer observed in the seven onward-TDR clusters, and from those only one was an active-TC. Unlike subtype B, the socio-demographic factors did not show any clear pattern.</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>Transmission cluster reconstruction has been previously used to understand HIV-1 and resistance transmission patterns in other settings [<xref rid="pone.0218226.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0218226.ref007" ref-type="bibr">7</xref>]. Herein, we combine and compare the information provided by classical statistical analyses of the most complete Portuguese cohort available, stratified by subtypes, with the one retrieved from transmission clusters analyses.</p><p>Through our detailed analyses of the Portuguese HIV-1 epidemic, we find strong indications that: 1) transmission of subtype B is associated with younger males; 2) transmission of subtype G is decreasing in Portugal and in the native Portuguese population; 3) transmission of drug resistance has different patterns: males living in <italic>Lisboa</italic> and <italic>Vale do Tejo</italic> regions drive the active and onward transmission of TDR, while this transmission is limited for subtype G and does not correlate with any socio-demographic factors.</p><p>Importantly, active transmission of subtype B in the last years has been driven by males residing in Lisbon. Although a source of uncertainty is the lack of risk factor information for a large part of our cohort, the consistency of our findings in different analyses suggest an important role of MSM living in Lisbon for this sub-epidemic. These results are consistent with other studies in Europe, Brazil or USA, where young MSMs have been identified as the main drivers of subtype B and TDR transmission [<xref rid="pone.0218226.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0218226.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0218226.ref007" ref-type="bibr">7</xref>]. More studies are needed to evaluate how tourism or migration may influence these results.</p><p>We observed a decline both in the prevalence and in the number of patients present in subtype G TCs in native Portuguese people since 2005 (<xref ref-type="fig" rid="pone.0218226.g002">Fig 2A</xref>). This indicates that transmission of subtype G strains is decreasing and that transmission has been limited in the last years. This sub-epidemic was unique in Europe and mainly circulating within Portugal. It was imported from West Africa, it was associated with intravenous drug users (IDUs) [<xref rid="pone.0218226.ref030" ref-type="bibr">30</xref>] and afterwards became also prevalent in heterosexuals. With the introduction of the needle and syringe program in 1993, new infections in IDUs declined and this could be potentially associated with the decrease of viral transmission together with the introduction of HAART in 1996 [<xref rid="pone.0218226.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0218226.ref031" ref-type="bibr">31</xref>]. This finding corroborates how a long-term effective prevention program impacted HIV-1 transmission.</p><p>While we described that TDR levels differ between subtypes, with higher levels for B, the overall TDR remains stable across time, which agrees with the European study SPREAD [<xref rid="pone.0218226.ref032" ref-type="bibr">32</xref>]. TC analyses indicates that onward transmission of TDR is limited and mainly associated with subtype B and with a decreasing proportion of involvement of treated population since 2006. A higher TDR level for subtype B for NRTIs and PIs could result from several factors: i) The earlier beginning of the treatment for subtype B patients than for subtype G, and/or ii) a lower fitness of G strains in presence of SDRMs, which would cause faster reversion and consequent lower transmissibility level of SDRMs; and/or iii) behavioral patterns affecting the G sub-epidemic dynamics, with slower transmission rates and therefore higher likelihood that SDRM revert before their onward transmission; and/or iv) different treatment strategies for each subtype, which is unlikely because these patients are treated in the same country with similar regimens.</p><p>Our results should be interpreted with caution due to the lack of information about the time of infection, risk of transmission, country of origin and limited representativeness for the North region of Portugal [<xref rid="pone.0218226.ref002" ref-type="bibr">2</xref>]. The BEST-HOPE project is prospectively collecting recent socio-demographic and behavioral data to complete the picture of the current patterns of transmission in the country [<xref rid="pone.0218226.ref033" ref-type="bibr">33</xref>]. Finally, phylogenetic analyses have intrinsic limitations since it does not provide information about sexual networks and depends on the sampling density [<xref rid="pone.0218226.ref034" ref-type="bibr">34</xref>].</p><p>In conclusion, we have shown different patterns of transmission of HIV-1 and resistance for the two most important sub-epidemics in Portugal: subtype B and G. Our findings suggest that long-term prevention policies have impacted the transmission of subtype G in Portugal and resulted in decrease of prevalence of this subtype, while subtype B is reflecting the current patterns of HIV-1 transmission that is happening in other European countries.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0218226.s001"><label>S1 File</label><caption><p><bold>Table A:</bold> Characteristics of the subtype B population in the PT-naive cohort between 2001 and 2014. Missing data was less than 5%, the exception were variables with an asterisk. CD4 count, risk of transmission and continent of origin were excluded from the multivariate analyses given the amount of missing data. Abbreviations: IQR: interquartile range, n: sample, TDR: transmitted drug resistance, % percentage.</p><p><bold>Table B:</bold> Characteristics of the subtype G population in the PT-naive cohort between 2001 and 2014. Missing data was less than 5%, the exception were variables with an asterisk. CD4 count, risk of transmission and continent of origin were excluded from the multivariate analyses given the amount of missing data. Abbreviations: IQR: interquartile range, n: sample, TDR: transmitted drug resistance, % percentage.</p><p><bold>Table C:</bold> Characteristics of the &#x0201c;pure&#x0201d; subtype G population in the PT-naive cohort between 2001 and 2014. Missing data was less than 5%, the exception were variables with an asterisk. CD4 count, risk of transmission and continent of origin were excluded from the multivariate analyses given the amount of missing data. Abbreviations: IQR: interquartile range, n: sample, TDR: transmitted drug resistance, % percentage.</p><p><bold>Table D:</bold>Table D. Characteristics of the transmission clusters (TCs) in the PT-naive cohort and in the PT-naive cohort with TDR for the &#x0201c;pure&#x0201d; subtype G. Abbreviations: IQR: interquartile range, n: sample, NS: No significant, TCs: Transmission clusters TDR: transmitted drug resistance, % percentage.</p><p>(DOCX)</p></caption><media xlink:href="pone.0218226.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank the patients and all the members of the Portuguese HIV-1 Resistance Study Group:</p><p>F&#x000e1;tima Gon&#x000e7;alves<sup>6</sup>, Isabel Diogo<sup>6</sup>, Joaquim Cabanas<sup>6</sup>, Ana Patr&#x000ed;cia Carvalho<sup>6</sup>, Sandra Fernandes<sup>6</sup>, In&#x000ea;s Costa<sup>6</sup>, Kamal Mansinho<sup>8</sup>, Ana Cl&#x000e1;udia Miranda<sup>8</sup>, Isabel Aldir<sup>8</sup>, Fernando Ventura<sup>8</sup>, Jaime Nina<sup>8</sup>, Fernando Borges<sup>8</sup>, Em&#x000ed;lia Valadas<sup>9</sup>, Manuela Doroana<sup>9</sup>, Francisco Antunes<sup>9</sup>, Nuno Marques<sup>10</sup>, Maria Jo&#x000e3;o Aleixo<sup>10</sup>, Maria Jo&#x000e3;o &#x000c1;guas<sup>10</sup>, J&#x000fa;lio Botas<sup>10</sup>, Teresa Branco<sup>11</sup>, Patr&#x000ed;cia Pacheco<sup>11</sup>, Lu&#x000ed;s Duque<sup>11</sup>, Jos&#x000e9; Vera<sup>12</sup>, Lu&#x000ed;s Tavares<sup>12</sup>, In&#x000ea;s Vaz Pinto<sup>13</sup>, Jos&#x000e9; Po&#x000e7;as<sup>14</sup>, Joana S&#x000e1;<sup>14</sup>, Ant&#x000f3;nio Diniz<sup>15</sup>, Margarida Serrado<sup>15</sup>, Ana Mineiro<sup>15</sup>, Flora Gomes<sup>16</sup>, Cristina Guerreiro<sup>16</sup>, Carlos Santos<sup>17</sup>, Domit&#x000ed;lia Faria<sup>17</sup>, Paula Fonseca<sup>17</sup>, Paula Proen&#x000e7;a<sup>18</sup>, Telo Faria<sup>19</sup>, Eug&#x000e9;nio Te&#x000f3;filo<sup>20</sup>, Sofia Pinheiro<sup>20</sup>, Isabel Germano<sup>21</sup>, Umbelina Caixas<sup>21</sup>, Margarida Bentes Jesus<sup>21</sup>, Nancy Faria<sup>22</sup>, Ana Paula Reis<sup>22</sup>, Gra&#x000e7;a Amaro<sup>23</sup>, Fausto Roxo<sup>23</sup>, Ricardo Abreu<sup>24</sup> and Isabel Neves<sup>24</sup>.</p><p>Affiliations:</p><p>6- Laborat&#x000f3;rio de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal</p><p>8- Servi&#x000e7;o de Doen&#x000e7;as Infeciosas, Centro Hospitalar de Lisboa Ocidental, Hospital de Egas Moniz, Lisbon, Portugal</p><p>9- Servi&#x000e7;o de Infeciologia, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Lisbon, Portugal</p><p>10- Servi&#x000e7;o de Infeciologia, Hospital Garcia da Orta, Almada, Portugal</p><p>11- Servi&#x000e7;o de Infeciologia, Hospital Dr. Fernando da Fonseca, Amadora, Portugal</p><p>12- Servi&#x000e7;o de Medicina Interna, Centro Hospitalar do Barreiro-Montijo, Portugal</p><p>13- Unidade funcional VIH/SIDA, Hospital de Cascais, Cascais, Portugal</p><p>14- Servi&#x000e7;o de Infeciologia, Centro Hospitalar de Set&#x000fa;bal, Set&#x000fa;bal, Portugal</p><p>15- Servi&#x000e7;o de Pneumologia, Hospital Pulido Valente, Centro Hospitalar de Lisboa Norte, Lisbon, Portugal</p><p>16- Servi&#x000e7;o de Obstetr&#x000ed;cia&#x02014;Maternidade Alfredo da Costa, Centro Hospitalar de Lisboa Central, Lisbon, Portugal</p><p>17- Servi&#x000e7;o de Medicina Interna-Centro Hospitalar do Algarve, Hospital de Portim&#x000e3;o, Portim&#x000e3;o, Portugal</p><p>18- Servi&#x000e7;o de Infeciologia-Centro Hospitalar do Algarve, Hospital de Faro, Faro, Portugal</p><p>19- Unidade Local de Sa&#x000fa;de do Baixo Alentejo, Hospital Jos&#x000e9; Joaquim Fernandes, Beja, Portugal</p><p>20- Servi&#x000e7;o de Infeciologia, Hospital de Santo Ant&#x000f3;nio dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal</p><p>21- Servi&#x000e7;o de Medicina 1.4, Centro Hospitalar de Lisboa Central, Hospital de S&#x000e3;o Jos&#x000e9;, Lisbon, Portugal</p><p>22- Servi&#x000e7;o de Doen&#x000e7;as Infectocontagiosas, Hospital Central do Funchal, Funchal, Madeira, Portugal</p><p>23- Servi&#x000e7;o de Doen&#x000e7;as Infeciosas, Hospital Distrital de Santar&#x000e9;m, Santar&#x000e9;m, Portugal</p><p>24- Servi&#x000e7;o de Infeciologia, Unidade de Local de Sa&#x000fa;de de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal</p><p>Lead author for group: Kamal Mansinho (<email>kmansinho@chlo.min-saude.pt</email>; <email>anacbcm@gmail.com</email>)</p></ack><ref-list><title>References</title><ref id="pone.0218226.ref001"><label>1</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control, World Health Organization. Regional Office for Europe. HIV/AIDS surveillance in Europe 2018. 2017 Data.</mixed-citation></ref><ref id="pone.0218226.ref002"><label>2</label><mixed-citation publication-type="other">Cortes Martins H, Aldir I. Infe&#x000e7;&#x000e3;o VIH e SIDA: a situa&#x000e7;&#x000e3;o em Portugal a 31 de dezembro de 2017 [Internet]. Lisboa: Instituto Nacional de Sa&#x000fa;de Doutor Ricardo Jorge, IP; 2018 Nov. Report No.: 149. Available: <ext-link ext-link-type="uri" xlink:href="http://hdl.handle.net/10400.18/5666">http://hdl.handle.net/10400.18/5666</ext-link></mixed-citation></ref><ref id="pone.0218226.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Ragonnet-Cronin</surname><given-names>ML</given-names></name>, <name><surname>Shilaih</surname><given-names>M</given-names></name>, <name><surname>G&#x000fc;nthard</surname><given-names>HF</given-names></name>, <name><surname>Hodcroft</surname><given-names>EB</given-names></name>, <name><surname>B&#x000f6;ni</surname><given-names>J</given-names></name>, <name><surname>Fearnhill</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>: <fpage>32251</fpage>
<pub-id pub-id-type="doi">10.1038/srep32251</pub-id>
<?supplied-pmid 27642070?><pub-id pub-id-type="pmid">27642070</pub-id></mixed-citation></ref><ref id="pone.0218226.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Esbj&#x000f6;rnsson</surname><given-names>J</given-names></name>, <name><surname>Mild</surname><given-names>M</given-names></name>, <name><surname>Audelin</surname><given-names>A</given-names></name>, <name><surname>Fonager</surname><given-names>J</given-names></name>, <name><surname>Skar</surname><given-names>H</given-names></name>, <name><surname>Bruun J&#x000f8;rgensen</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries</article-title>. <source>Virus Evol</source>. <year>2016</year>;<volume>2</volume>: vew010. <pub-id pub-id-type="doi">10.1093/ve/vew010</pub-id>
<?supplied-pmid 27774303?><pub-id pub-id-type="pmid">27774303</pub-id></mixed-citation></ref><ref id="pone.0218226.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Pineda-Pe&#x000f1;a</surname><given-names>A-C</given-names></name>, <name><surname>Theys</surname><given-names>K</given-names></name>, <name><surname>Stylianou</surname><given-names>DC</given-names></name>, <name><surname>Demetriades</surname><given-names>I</given-names></name>, <collab>SPREAD/ESAR Program</collab>, <name><surname>Abecasis</surname><given-names>AB</given-names></name>, <etal>et al</etal>
<article-title>HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>: <fpage>1702</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-19080-5</pub-id>
<?supplied-pmid 29374182?><pub-id pub-id-type="pmid">29374182</pub-id></mixed-citation></ref><ref id="pone.0218226.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Pineda-Pe&#x000f1;a </surname><given-names>A-C</given-names></name>, <name><surname>Schrooten</surname><given-names>Y</given-names></name>, <name><surname>Vinken</surname><given-names>L</given-names></name>, <name><surname>Ferreira</surname><given-names>F</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <name><surname>Trov&#x000e3;o</surname><given-names>NS</given-names></name>, <etal>et al</etal>
<article-title>Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic</article-title>. <source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>: <fpage>e101738</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0101738</pub-id>
<?supplied-pmid 25003369?><pub-id pub-id-type="pmid">25003369</pub-id></mixed-citation></ref><ref id="pone.0218226.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Wertheim</surname><given-names>JO</given-names></name>, <name><surname>Kosakovsky Pond</surname><given-names>SL</given-names></name>, <name><surname>Forgione</surname><given-names>LA</given-names></name>, <name><surname>Mehta</surname><given-names>SR</given-names></name>, <name><surname>Murrell</surname><given-names>B</given-names></name>, <name><surname>Shah</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Social and Genetic Networks of HIV-1 Transmission in New York City</article-title>. <source>PLoS Pathog</source>. <year>2017</year>;<volume>13</volume>: <fpage>e1006000</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1006000</pub-id>
<?supplied-pmid 28068413?><pub-id pub-id-type="pmid">28068413</pub-id></mixed-citation></ref><ref id="pone.0218226.ref008"><label>8</label><mixed-citation publication-type="other">Conselho Cient&#x000ed;fico do Programa Nacional para a Infe&#x000e7;&#x000e3;o VIH/SIDA. Recomenda&#x000e7;&#x000f5;es Portuguesas para o tratamento da infe&#x000e7;&#x000e3;o por VIH-1 e VIH-2 (2016 vers&#x000e3;o 1.0). Programa Nacional para a Infe&#x000e7;&#x000e3;o VIH/SIDA;</mixed-citation></ref><ref id="pone.0218226.ref009"><label>9</label><mixed-citation publication-type="book"><collab>EACS European AIDS Clinical Society</collab>. <source>European Guidelines for treatment of HIV-positive adults in Europe version 9.1</source>. [Internet]. <publisher-name>European AIDS Clinical Society (EACS)</publisher-name>; <year>2018</year> Available: <ext-link ext-link-type="uri" xlink:href="http://www.eacsociety.org">http://www.eacsociety.org</ext-link></mixed-citation></ref><ref id="pone.0218226.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Wittkop</surname><given-names>L</given-names></name>, <name><surname>G&#x000fc;nthard</surname><given-names>HF</given-names></name>, <name><surname>de Wolf</surname><given-names>F</given-names></name>, <name><surname>Dunn</surname><given-names>D</given-names></name>, <name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>, <name><surname>de Luca</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>: <fpage>363</fpage>&#x02013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(11)70032-9</pub-id>
<?supplied-pmid 21354861?><pub-id pub-id-type="pmid">21354861</pub-id></mixed-citation></ref><ref id="pone.0218226.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Palma</surname><given-names>AC</given-names></name>, <name><surname>Ara&#x000fa;jo</surname><given-names>F</given-names></name>, <name><surname>Duque</surname><given-names>V</given-names></name>, <name><surname>Borges</surname><given-names>F</given-names></name>, <name><surname>Paix&#x000e3;o</surname><given-names>MT</given-names></name>, <name><surname>Camacho</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal</article-title>. <source>Infect Genet Evol</source>. <year>2007</year>;<volume>7</volume>: <fpage>391</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2007.01.009</pub-id>
<?supplied-pmid 17360244?><pub-id pub-id-type="pmid">17360244</pub-id></mixed-citation></ref><ref id="pone.0218226.ref012"><label>12</label><mixed-citation publication-type="other">UNAIDS. Joint United Nations Programme on HIV/AIDS. Global AIDS Update 2018&#x02014;Miles to Go: Closing Gaps, Breaking Barriers, Righting Injustices. 2018.</mixed-citation></ref><ref id="pone.0218226.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ssemwanga</surname><given-names>D</given-names></name>, <name><surname>Lihana</surname><given-names>RW</given-names></name>, <name><surname>Ugoji</surname><given-names>C</given-names></name>, <name><surname>Abimiku</surname><given-names>A</given-names></name>, <name><surname>Nkengasong</surname><given-names>J</given-names></name>, <name><surname>Dakum</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Update on HIV-1 acquired and transmitted drug resistance in Africa</article-title>. <source>AIDS Rev</source>. <year>2015</year>;<volume>17</volume>: <fpage>3</fpage>&#x02013;<lpage>20</lpage>. <?supplied-pmid 25427100?><pub-id pub-id-type="pmid">25427100</pub-id></mixed-citation></ref><ref id="pone.0218226.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Abecasis</surname><given-names>AB</given-names></name>, <name><surname>Wensing</surname><given-names>AMJ</given-names></name>, <name><surname>Paraskevis</surname><given-names>D</given-names></name>, <name><surname>Vercauteren</surname><given-names>J</given-names></name>, <name><surname>Theys</surname><given-names>K</given-names></name>, <name><surname>Van de Vijver</surname><given-names>DAMC</given-names></name>, <etal>et al</etal>
<article-title>HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics</article-title>. <source>Retrovirology</source>. <year>2013</year>;<volume>10</volume>: <fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/1742-4690-10-7</pub-id>
<?supplied-pmid 23317093?><pub-id pub-id-type="pmid">23317093</pub-id></mixed-citation></ref><ref id="pone.0218226.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Esteves</surname><given-names>A</given-names></name>, <name><surname>Parreira</surname><given-names>R</given-names></name>, <name><surname>Venenno</surname><given-names>T</given-names></name>, <name><surname>Franco</surname><given-names>M</given-names></name>, <name><surname>Piedade</surname><given-names>J</given-names></name>, <name><surname>Germano De Sousa</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2002</year>;<volume>18</volume>: <fpage>313</fpage>&#x02013;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1089/088922202753519089</pub-id>
<?supplied-pmid 11897032?><pub-id pub-id-type="pmid">11897032</pub-id></mixed-citation></ref><ref id="pone.0218226.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Libin</surname><given-names>P</given-names></name>, <name><surname>Beheydt</surname><given-names>G</given-names></name>, <name><surname>Deforche</surname><given-names>K</given-names></name>, <name><surname>Imbrechts</surname><given-names>S</given-names></name>, <name><surname>Ferreira</surname><given-names>F</given-names></name>, <name><surname>Van Laethem</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>RegaDB: community-driven data management and analysis for infectious diseases</article-title>. <source>Bioinformatics</source>. <year>2013</year>;<volume>29</volume>: <fpage>1477</fpage>&#x02013;<lpage>1480</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt162</pub-id>
<?supplied-pmid 23645815?><pub-id pub-id-type="pmid">23645815</pub-id></mixed-citation></ref><ref id="pone.0218226.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>DE</given-names></name>, <name><surname>Camacho</surname><given-names>RJ</given-names></name>, <name><surname>Otelea</surname><given-names>D</given-names></name>, <name><surname>Kuritzkes</surname><given-names>DR</given-names></name>, <name><surname>Fleury</surname><given-names>H</given-names></name>, <name><surname>Kiuchi</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update</article-title>. <source>PLoS ONE</source>. <year>2009</year>;<volume>4</volume>: <fpage>e4724</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004724</pub-id>
<?supplied-pmid 19266092?><pub-id pub-id-type="pmid">19266092</pub-id></mixed-citation></ref><ref id="pone.0218226.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Alcantara</surname><given-names>LCJ</given-names></name>, <name><surname>Cassol</surname><given-names>S</given-names></name>, <name><surname>Libin</surname><given-names>P</given-names></name>, <name><surname>Deforche</surname><given-names>K</given-names></name>, <name><surname>Pybus</surname><given-names>OG</given-names></name>, <name><surname>Van Ranst</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences</article-title>. <source>Nucleic Acids Res</source>. <year>2009</year>;<volume>37</volume>: <fpage>W634</fpage>&#x02013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkp455</pub-id>
<?supplied-pmid 19483099?><pub-id pub-id-type="pmid">19483099</pub-id></mixed-citation></ref><ref id="pone.0218226.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Pineda-Pe&#x000f1;a</surname><given-names>A-C</given-names></name>, <name><surname>Faria</surname><given-names>NR</given-names></name>, <name><surname>Imbrechts</surname><given-names>S</given-names></name>, <name><surname>Libin</surname><given-names>P</given-names></name>, <name><surname>Abecasis</surname><given-names>AB</given-names></name>, <name><surname>Deforche</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools</article-title>. <source>Infect Genet Evol</source>. <year>2013</year>;<volume>19</volume>: <fpage>337</fpage>&#x02013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2013.04.032</pub-id>
<?supplied-pmid 23660484?><pub-id pub-id-type="pmid">23660484</pub-id></mixed-citation></ref><ref id="pone.0218226.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Struck</surname><given-names>D</given-names></name>, <name><surname>Lawyer</surname><given-names>G</given-names></name>, <name><surname>Ternes</surname><given-names>A-M</given-names></name>, <name><surname>Schmit</surname><given-names>J-C</given-names></name>, <name><surname>Bercoff</surname><given-names>DP</given-names></name>. <article-title>COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>: <fpage>e144</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gku739</pub-id>
<?supplied-pmid 25120265?><pub-id pub-id-type="pmid">25120265</pub-id></mixed-citation></ref><ref id="pone.0218226.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>B&#x000e1;rtolo</surname><given-names>I</given-names></name>, <name><surname>Abecasis</surname><given-names>AB</given-names></name>, <name><surname>Borrego</surname><given-names>P</given-names></name>, <name><surname>Barroso</surname><given-names>H</given-names></name>, <name><surname>McCutchan</surname><given-names>F</given-names></name>, <name><surname>Gomes</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Origin and epidemiological history of HIV-1 CRF14_BG</article-title>. <source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>: <fpage>e24130</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0024130</pub-id>
<?supplied-pmid 21969855?><pub-id pub-id-type="pmid">21969855</pub-id></mixed-citation></ref><ref id="pone.0218226.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Kuiken</surname><given-names>C</given-names></name>, <name><surname>Korber</surname><given-names>B</given-names></name>, <name><surname>Shafer</surname><given-names>RW</given-names></name>. <article-title>HIV sequence databases</article-title>. <source>AIDS Rev</source>. <year>2003</year>;<volume>5</volume>: <fpage>52</fpage>&#x02013;<lpage>61</lpage>. <?supplied-pmid 12875108?><pub-id pub-id-type="pmid">12875108</pub-id></mixed-citation></ref><ref id="pone.0218226.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Edgar</surname><given-names>RC</given-names></name>. <article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput</article-title>. <source>Nucleic Acids Res</source>. <year>2004</year>;<volume>32</volume>: <fpage>1792</fpage>&#x02013;<lpage>1797</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkh340</pub-id>
<?supplied-pmid 15034147?><pub-id pub-id-type="pmid">15034147</pub-id></mixed-citation></ref><ref id="pone.0218226.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Libin</surname><given-names>P</given-names></name>, <name><surname>Deforche</surname><given-names>K</given-names></name>, <name><surname>Abecasis</surname><given-names>AB</given-names></name>, <name><surname>Theys</surname><given-names>K</given-names></name>. <article-title>VIRULIGN: fast codon-correct alignment and annotation of viral genomes</article-title>. <source>Bioinformatics</source>. <year>2018</year>; <pub-id pub-id-type="doi">10.1093/bioinformatics/bty851</pub-id>
<?supplied-pmid 30295730?><pub-id pub-id-type="pmid">30295730</pub-id></mixed-citation></ref><ref id="pone.0218226.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Ragonnet-Cronin</surname><given-names>M</given-names></name>, <name><surname>Hodcroft</surname><given-names>E</given-names></name>, <name><surname>Hu&#x000e9;</surname><given-names>S</given-names></name>, <name><surname>Fearnhill</surname><given-names>E</given-names></name>, <name><surname>Delpech</surname><given-names>V</given-names></name>, <name><surname>Brown</surname><given-names>AJL</given-names></name>, <etal>et al</etal>
<article-title>Automated analysis of phylogenetic clusters</article-title>. <source>BMC Bioinformatics</source>. <year>2013</year>;<volume>14</volume>: <fpage>317</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-14-317</pub-id>
<?supplied-pmid 24191891?><pub-id pub-id-type="pmid">24191891</pub-id></mixed-citation></ref><ref id="pone.0218226.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Drummond</surname><given-names>AJ</given-names></name>, <name><surname>Suchard</surname><given-names>MA</given-names></name>, <name><surname>Xie</surname><given-names>D</given-names></name>, <name><surname>Rambaut</surname><given-names>A</given-names></name>. <article-title>Bayesian phylogenetics with BEAUti and the BEAST 1.7</article-title>. <source>Mol Biol Evol</source>. <year>2012</year>;<volume>29</volume>: <fpage>1969</fpage>&#x02013;<lpage>1973</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/mss075</pub-id>
<?supplied-pmid 22367748?><pub-id pub-id-type="pmid">22367748</pub-id></mixed-citation></ref><ref id="pone.0218226.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Rambaut</surname><given-names>A</given-names></name>, <name><surname>Lam</surname><given-names>TT</given-names></name>, <name><surname>Max Carvalho</surname><given-names>L</given-names></name>, <name><surname>Pybus</surname><given-names>OG</given-names></name>. <article-title>Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen)</article-title>. <source>Virus Evol</source>. <year>2016</year>;<volume>2</volume>: vew007. <pub-id pub-id-type="doi">10.1093/ve/vew007</pub-id>
<?supplied-pmid 27774300?><pub-id pub-id-type="pmid">27774300</pub-id></mixed-citation></ref><ref id="pone.0218226.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>MS</given-names></name>, <name><surname>Lemey</surname><given-names>P</given-names></name>, <name><surname>Faria</surname><given-names>NR</given-names></name>, <name><surname>Rambaut</surname><given-names>A</given-names></name>, <name><surname>Shapiro</surname><given-names>B</given-names></name>, <name><surname>Suchard</surname><given-names>MA</given-names></name>. <article-title>Improving Bayesian population dynamics inference: a coalescent-based model for multiple loci</article-title>. <source>Mol Biol Evol</source>. <year>2013</year>;<volume>30</volume>: <fpage>713</fpage>&#x02013;<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/mss265</pub-id>
<?supplied-pmid 23180580?><pub-id pub-id-type="pmid">23180580</pub-id></mixed-citation></ref><ref id="pone.0218226.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Yebra</surname><given-names>G</given-names></name>, <name><surname>Holgu&#x000ed;n</surname><given-names>A</given-names></name>, <name><surname>Pillay</surname><given-names>D</given-names></name>, <name><surname>Hu&#x000e9;</surname><given-names>S</given-names></name>. <article-title>Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain</article-title>. <source>Infect Genet Evol</source>. <year>2013</year>;<volume>14</volume>: <fpage>232</fpage>&#x02013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2012.12.006</pub-id>
<?supplied-pmid 23291408?><pub-id pub-id-type="pmid">23291408</pub-id></mixed-citation></ref><ref id="pone.0218226.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Esteves</surname><given-names>A</given-names></name>, <name><surname>Parreira</surname><given-names>R</given-names></name>, <name><surname>Piedade</surname><given-names>J</given-names></name>, <name><surname>Venenno</surname><given-names>T</given-names></name>, <name><surname>Franco</surname><given-names>M</given-names></name>, <name><surname>Germano de Sousa</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Spreading of HIV-1 subtype G and envB/gagG recombinant strains among injecting drug users in Lisbon, Portugal</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2003</year>;<volume>19</volume>: <fpage>511</fpage>&#x02013;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1089/088922203766774568</pub-id>
<?supplied-pmid 12892060?><pub-id pub-id-type="pmid">12892060</pub-id></mixed-citation></ref><ref id="pone.0218226.ref031"><label>31</label><mixed-citation publication-type="other">Dire&#x000e7;&#x000e3;o-Geral da Sa&#x000fa;de. Programa diz n&#x000e3;o a uma seringa em segunda m&#x000e3;o, Kit Preven&#x000e7;&#x000e3;o. Programa Nacional para a Infe&#x000e7;&#x000e3;o VIH/SIDA; 2013.</mixed-citation></ref><ref id="pone.0218226.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Hofstra</surname><given-names>LM</given-names></name>, <name><surname>Sauvageot</surname><given-names>N</given-names></name>, <name><surname>Albert</surname><given-names>J</given-names></name>, <name><surname>Alexiev</surname><given-names>I</given-names></name>, <name><surname>Garcia</surname><given-names>F</given-names></name>, <name><surname>Struck</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe</article-title>. <source>Clin Infect Dis</source>. <year>2016</year>;<volume>62</volume>: <fpage>655</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ963</pub-id>
<?supplied-pmid 26620652?><pub-id pub-id-type="pmid">26620652</pub-id></mixed-citation></ref><ref id="pone.0218226.ref033"><label>33</label><mixed-citation publication-type="other">Pingarilho M, Pineda-Pe&#x000f1;a A-C, Gomes P, Pimentel VF, Libin P, Theys K, et al. BEST HOPE&#x02014;Cohort of newly diagnosed patients in Portugal. XI congresso nacional de VIH/SIDA e XIII congresso nacional de Doen&#x000e7;as Infecciosas e Microbiologia cl&#x000ed;nica 2016; 2016; Coimbra, Portugal.</mixed-citation></ref><ref id="pone.0218226.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Brenner</surname><given-names>B</given-names></name>, <name><surname>Wainberg</surname><given-names>MA</given-names></name>, <name><surname>Roger</surname><given-names>M</given-names></name>. <article-title>Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions</article-title>. <source>AIDS</source>. <year>2013</year>;<volume>27</volume>: <fpage>1045</fpage>&#x02013;<lpage>1057</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32835cffd9</pub-id>
<?supplied-pmid 23902920?><pub-id pub-id-type="pmid">23902920</pub-id></mixed-citation></ref></ref-list></back></article>